Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

April 29, 2019

Medicated Mouthwashes May Help to Reduce Oral Mucositis-Related Pain

Author(s):

Kristie L. Kahl

Use of two medicated mouthwashes reduced pain from oral mucositis during the first four hours after administration; however, the results were not deemed clinically different when compared with placebo.

Use of two medicated mouthwashes reduced pain from oral mucositis during the first four hours after administration; however, the results were not deemed clinically different when compared with placebo, according to study results published in JAMA.

Oral mucositis is a side effect from radiotherapy and chemotherapy, causing pain, and in turn, discontinuation of treatment for many with cancer. “Symptoms can be severe, and oral mucositis can lead to hospitalization and requirement of a feeding tube,” the researchers wrote. “More than 80% of patients develop oral mucositis during radiotherapy, and mouthwashes and systemic analgesic agents are frequently used to treat the condition.”

While a number of commercially-available combination mouthwashes exist, no trials support their use for oral mucositis induced by cancer treatment.

So, the researchers conducted a randomized phase 3 trial designed to evaluate whether a single dose of doxepin mouthwash (92 patients) or diphenhydramine-lidocaine-antacid mouthwash (92 patients) was more effective than placebo (92 patients) in reducing oral mucositis pain for patients undergoing radiotherapy to the oral cavity for head and neck cancer treatment.

Total pain reduction during the four hours after a single dose of the mouthwashes compared with placebo served as the primary endpoint, with a minimal clinically important difference being a 3.5-point change. Secondary endpoints included drowsiness, unpleasant taste and stinging or burning. All scales ranged from 0 (best) to 10 (worst).

Patients were a median age of 61 years, and the majority were men (79%). Only 227 patients completed treatment per protocol.

Mucositis pain during the first 4 hours decreased by 11.6 points in the doxepin mouthwash group, by 11.7 points in the diphenhydramine- lidocaine-antacid mouthwash group and by 8.7 points in the placebo group, for a 2.9-point difference between doxepin mouthwash and placebo and a 3.0-point difference between diphenhydramine- lidocaine-antacid mouthwash and placebo.

Patients who received doxepin mouthwash reported more drowsiness (by 1.5 points), unpleasant taste (by 1.5 points) and stinging or burning (by 4.0 points) compared with placebo.

Grade 3 side effects occurred in three patients who received the doxepin mouthwash, three patients with the diphenhydramine-lidocaine-antacid mouthwash and two patients with placebo. In addition, fatigue was reported by five patients in the doxepin mouthwash group and no patients in the diphenhydramine- lidocaine-antacid mouthwash group.

“Among patients undergoing head and neck radiotherapy, the use of doxepin mouthwash or diphenhydramine-lidocaine- antacid mouthwash compared with placebo significantly reduced oral mucositis pain during the first four hours after administration; however, the effect size was less than the minimal clinically important difference,” the researchers wrote. “Further research is needed to assess longer-term efficacy and safety for both mouthwashes.”

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Image of bald man.
Image of man with black hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Dr. Michael Moore
Related Content
Advertisement
Image of Dr. with text
June 26th 2025

Eating Tips for When Cancer Treatment Makes Meals Challenging

Spencer Feldman
Greek yogurt, egg salad, avocado and mac and cheese are easy-to-swallow, high-calorie foods that can help patients maintain strength during cancer treatment.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck: © stock.adobe.com.
June 1st 2025

Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer

Ariana Pelosci
Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Image of woman holding her neck.
May 5th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
Illustration of neck.
April 25th 2025

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

Alex Biese
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.
Related Content
Advertisement
Image of Dr. with text
June 26th 2025

Eating Tips for When Cancer Treatment Makes Meals Challenging

Spencer Feldman
Greek yogurt, egg salad, avocado and mac and cheese are easy-to-swallow, high-calorie foods that can help patients maintain strength during cancer treatment.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck: © stock.adobe.com.
June 1st 2025

Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer

Ariana Pelosci
Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Image of woman holding her neck.
May 5th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
Illustration of neck.
April 25th 2025

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

Alex Biese
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.